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For clinical trials of anti-infective drugs for the treatment of vascular access device—related
bloodstream infections, patients should be identified and enrolled on the basis of current stan-
dards for the clinical diagnosis of such infections. To ensure comparability of patients, only those
infected with staphylococci and Candida species should be included. A prospective, randomized,
double-blind design is recommended. Future protocols may include abbreviated courses of ther-
apy, treatment with combinations of drugs, or a progression from parenteral to oral therapy.
Clinical response is judged as cure, failure, or indeterminate response; there is no "improved"
category. Microbiological response is categorized as eradication, persistence, or relapse and is of
paramount importance. Several months of follow-up may be necessary for the detection of late
relapses or metastatic infections. This guideline does not apply to studies of bacteremia or funge-
mia secondary to non-device-related, organ-based primary infections (e.g., pneumonia, urinary
tract infection), which should be assessed in relation to the primary disorder.
I. INTRODUCTION
This guideline is one of a series of disease-specific guide-
lines that have been prepared to assist sponsors and investi-
gators in the development, conduct, and analysis of studies
of new anti-infective drugs. This guideline deals with the
conduct of phase 1 through phase 4 clinical trials and is a
subset of the General Guidelines for the Clinical Evaluation
of Anti-Infective Drug Products and of the European Guide-
lines for the Clinical Evaluation of Anti-Infective Drug Prod-
ucts [ 1 ], which should be consulted for the prerequisites to
the conduct of studies in humans. Lack of coverage in this
specific guideline of issues covered by the General Guide-
lines does not imply that these issues are unimportant.
A. Standards of Care
The standards of care for vascular access device—asso-
ciated bloodstream infections are based on the patient's his-
tory, the natural history of the disease, and currently avail-
able therapy [2-4]. These infections pose an expanding
problem. Invasive therapeutic and monitoring devices,
which are being used with increasing frequency and which
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compromise the vascular integrity of hospitalized patients
and of other individualsas well (e.g., those undergoing paren-
teral therapy at home), provide a route by which pathogens
can gain access to the bloodstream and cause metastatic in-
fection. Factors such as the type and nature of the device, its
anatomic site, the duration of its use, the quality of local care
at cutaneous access sites, and other medical practices may
influence the frequency and nature of these infections. The
clinical presentation of fever, phlebitis proximal to the cuta-
neous entry site, and hypotension suggests this diag-
nosis.
1. Bacteremia
Device-associated bacteremia frequently involves Staphy-
lococcus aureus and coagulase-negative staphylococci. Gram-
negative bacilli and Streptococcus pyogenes are less fre-
quently involved.
2. Fungemia
Candida species are the fungi most frequently responsible
for device-related infection. As there is no well-defined or
established standard of therapy for device-associated funge-
mia, use of historical control groups cannot be recom-
mended. In vitro susceptibility to antifungal agents varies
among species, and this variability must be considered in the
selection of treatment.
3. Confounding Factors
Devices impregnated with anti-infective substances are
now employed in many health-care settings. Their use may
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influence the nature of the infecting organisms and may con-
found analyses of the safety and efficacy of study drugs [5].
B. Scope of the Guideline
1. Clinical Entities Included
This guideline applies to protocols for evaluation of the
safety and efficacy of new anti-infective drugs in the treat-
ment of device-associated bloodstream infections due to
Staphylococcus and Candida species. Peripheral or central in-
travenous devices, venous or arterial pressure monitoring de-
vices, pacemakers, and balloon-assist devices are all poten-
tial sources of such infections.
2. Clinical Entities Not Included
This guideline does not cover device-associated blood-
stream infections due to organisms other than Staphylococ-
cus or Candida species, local device-associated infections
without evidence of bloodstream involvement, or secondary
bloodstream infections related to underlying organ-based pa-
thology (e.g., pneumonia).
C. Future Trends
At present, the diagnosis of device-related bloodstream in-
fections is founded on the growth of a bacterial or fungal
species from cultures of a removed device and the demonstra-
tion of the same organism in cultures of venous blood drawn
when the device was in place. The use of surrogate markers,
such as microbial antigens in body fluids, for the diagnosis of
device-related bloodstream infections in clinical trials is not
currently recommended.
Interpretation of a positive culture of a removed device is
not always straightforward. Semiquantitative cultures should
be performed and interpreted by established criteria [6].
II. DEFINITIONS OF THE DISEASE
Both clinical and blood-culture criteria can be useful for
the definition of device-associated bloodstream infection.
A. Device-Associated Bacteremia
Definite device-associated bacteremia is defined by one or
more cultures of removed device surfaces that are positive for
a given organism in addition to two cultures of venous blood
that are obtained from a site remote from the device and are
positive for the same organism [6]. The isolation of different
organisms from device surfaces and blood should be desig-
nated "unable to evaluate." Culture of catheter hubs is not
an acceptable diagnostic technique for clinical trials. Proba-
ble device-associated bacteremia is defined by positive cul-
tures of the same organism from two separate venous-blood
samples obtained from a site remote from the device with an
intervening interval of >1 5 minutes. Possible device-asso-
ciated bacteremia is defined by two positive cultures of the
same organism from blood aspirated from the device or by
two positive cultures of the same organism from purulent
material collected from the cutaneous entry site.
B. Device-Associated Fungemia
The criteria for the definition of device-associated funge-
mia are the same as those for device-associated bacteremia.
The isolation of Candida species from a single blood culture
may be sufficient for a given study, but the use of this crite-
rion must be clearly justified in the protocol.
III. INFORMATION NEEDED BEFORE
CONDUCTING CLINICAL TRIALS
A. In Vitro Studies
An antimicrobial drug subjected to clinical trials of ther-
apy for bacteremia or fungemia must exhibit in vitro activity
against the pathogens whose isolation is anticipated. The
number of strains tested for susceptibility should be suffi-
cient for the accurate determination of the MIC 90 . Auto-
mated or tube dilution methods may be employed with
standard microbiological techniques. The method for deter-
mining the MIC should be stated clearly in the protocol. The
size of the inoculum should conform to that used in standard-
ized methods and should be explicitly described in the proto-
col. Determinations of the MBC, the serum bactericidal titer,
time-kill curves, or other indicators of in vitro antimicrobial
activity are desirable but not required. Because the results of
such tests are highly dependent on the method being used,
methods must be described in detail. The inoculum size
should be adequate to determine >99.9% killing and to mini-
mize or eliminate antimicrobial carry-over. The techniques
used for obtaining samples and processing blood cultures
should be specified clearly. The source of cultured blood
(i.e., blood collected by phlebotomy vs. blood aspirated from
the implicated device) must be stated. The in vitro suscepti-
bility of fungi to drugs is poorly predictive of in vivo efficacy.
Therefore, other justification must be provided to regulatory
authorities for the selection of particular drugs and regimens
to be studied.
B. In Vivo Studies
It is desirable (especially with regard to antifungal chemo-
therapy) to conduct tests with animal models of experimen-
tal infection before trials are initiated in humans. To date,
the extrapolation of results from animal models to humans
has resulted in more accurate prediction of the failure of a
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specific antimicrobial regimen than of its success. Clinical
trials in humans may not be justified if a drug has been
shown to be ineffective in experimental bloodstream infec-
tion at dosages thought to be applicable to humans. For both
bacteremia and fungemia, studies of animal models of endo-
carditis may be appropriate before trials involving patients
are initiated. [8-10].
IV. QUALIFICATIONS OF INVESTIGATORS AND
INSTITUTIONS
A. Investigators
See General Guidelines [ 1 ], section VII.
B. Institutions
The institution conducting a clinical trial should have a
clinical microbiology laboratory that can perform the follow-
ing tests: (1) determination of the MIC; (2) determination of
the concentration of an antimicrobial drug in serum; and (3)
identification (to the species level) of microorganisms recov-
ered from cultures of blood, access sites, and/or removed
devices. Alternatively, participating centers may refer sam-
ples for processing at a single laboratory that is certified by
recognized authorities and employs personnel skilled in the
procedures to be used.
V. DESIGN AND IMPLEMENTATION OF PHASE 1,
2, AND 3 CLINICAL TRIALS
See General Guidelines [1], sections III and VI.
VI. ELEMENTS TO BE CONSIDERED IN
DESIGNING PHASE 2 AND 3 CLINICAL TRIALS
A. General Considerations and Demographic Characteristics
The number of evaluable patients in each arm of a study
should be sufficient to detect clinically important differ-
ences, as defined in the protocol. There are no underlying
illnesses that absolutely preclude participation. No age limita-
tions for participants are standard, although phase 1 studies
may indicate that such limitations are needed. Studies of
children should be conducted separately from those of adults
whenever feasible.
While two well-controlled studies are recommended, a
single, well-designed, randomized, controlled, and prefera-
bly double-blind study of adequate size may, under certain
circumstances, be considered an adequate basis for registra-
tion of a new anti-infective agent.
B. Inclusion Criteria
Patients enrolled in clinical trials should have a clinical
picture including signs and symptoms of acute infection
(e.g., fever, rigors, inflammatory phlebitis in the device ac-
cess area) plus isolation of an appropriate pathogen from
cultures of (1) blood (obtained via the device or by periph-
eral phlebotomy), (2) a roll-plate sample from the removed
device surface, and/or (3) the device access site.
C. Exclusion Criteria
See General Guidelines [ 1 ], section IX. B. In addition, pa-
tients with the following conditions should not be enrolled:
(1) more than 24 hours of prior therapy with an antimicro-
bial agent active in vitro against the isolated pathogen; (2)
hypersensitivity to the study drugs; (3) pregnancy; (4) severe
renal dysfunction or hepatic dysfunction unless otherwise
specified in the protocol; or (5) evidence of acute urinary
tract, pulmonary, or abdominal infection or of another (non-
device) potential source of bloodstream infection.
If antimicrobial agent—impregnated device/catheter sub-
stances are used in a study, the protocol must include specific
justification for their use.
D. Special Conditions
(1) Specific details of device management (e.g., device-
site care, device removal before or during therapy, device
replacement) must be recorded along with temporal refer-
ences to therapy and diagnosis.
(2) Inflammatory phlebitis should be quantified when
present. Photographic documentation is desirable but not re-
quired.
(3) Consideration should be given to stratification for trial
design, such as (a) type of catheter (peripheral vs. central/
long-dwell); (b) management of the device (i.e., removal of
the implicated device before or during therapy, leaving the
device in place throughout the study, or placement of a new
device over a guidewire at the initial infection site); (c) inclu-
sion or exclusion of neutropenic hosts; and (d) type of mate-
rial making up the device.
(4) Local device-site care procedures, as addressed in
the protocol, should be standardized as much as possible
[7, 11, 12].
E. Selection of the Comparison Drug(s)
The drugs chosen for comparison with the study drug(s) in
studies of bacteremia must be active against the presumptive
staphylococcal pathogens (e.g., vancomycin). The agents se-
lected for comparisons in studies of fungemia must be active
against Candida species (e.g., amphotericin B); azole anti-
fungal drugs may be acceptable comparison agents in some
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settings, but their use for the treatment of immunocompe-
tent patients is still being investigated.
Noncomparative trials of device-related bacteremia or
fungemia require justification.
F. Study Design
All studies should be (1) double-blind, unless this type of
design is precluded by the choice of the comparison formula-
tion (e.g., amphotericin B) or by other conditions; (2) ran-
domized; (3) stratified (with a maximum of three strata pre
hoc); and (4) structured to include statistical-power assump-
tions that allow for the detection of clinically relevant differ-
ences (see General Guidelines, section XV and Appendix).
Whenever possible, studies should be prospective. Studies
should be designed to ensure that no more than 25% of cases
are within the "possible" category (see section II of this guide-
line) or involve atypical devices, such as pacemakers. All
protocols should be designed to include information on de-
vice dwell time before infection and on access-site care. See
General Guidelines [ 1 ], section XI, for further discussion of
issues arising in the design and stratification of studies.
G. Administration of the Study Drug
Initial treatment with the study drug in phase 2 or phase 3
trials should be based on preclinical investigations that dem-
onstrate efficacy in vitro and (when possible) in animal mod-
els. Choices regarding dosage, schedule, and other pharmaco-
kinetic considerations should be based on the results of
previously completed phase 1 trials supporting the safety and
efficacy of the drug in question. Antimicrobial susceptibility
should be assessed in vitro as soon as an etiologic organism is
isolated. Should the strain be resistant to the test drug, the
study should be terminated and the patient given an antimi-
crobial drug known to be effective against the causative mi-
croorganism, unless prior approval from regulatory authori-
ties has been obtained.
In the initial studies, the duration of therapy with the test
drug should be the same as that of treatment with standard
agents. If outpatient therapy is considered desirable or feasi-
ble, patients must be examined regularly for evidence of clin-
ical or microbiological failure of treatment and for toxic or
adverse effects. In addition, compliance with outpatient ther-
apy must be ensured.
Depending on the pharmacological and antimicrobial
characteristics of the study drug, it may be possible to switch
from parenteral to oral therapy. The protocol should state
clearly the point at which such a conversion may take place
and the measures that are planned to ensure adequate ab-
sorption of an orally administered drug. The duration of ther-
apy should be clearly defined in the protocol (usually, a min-
imum of 7-10 days) [2, 11, 13].
H. Definition of Response to Therapy
1. Clinical Response
The primary measures of efficacy should be clearly de-
scribed in the protocol. Clinical responses can be classified as
cure (resolution of all signs or symptoms noted at enroll-
ment); failure (persistence of presenting signs or symptoms,
development after enrollment of any new unfavorable find-
ings relating to efficacy measures, and/or removal of the im-
plicated device after initiation of therapy); or indeterminate
(antimicrobial therapy during the period of follow-up that
precludes clinical evaluation). Therapy resulting in an inde-
terminate response must be justified in the case report form.
If such justification is lacking, the case should be categorized
as a failure.
2. Microbiological Response
Cultures of samples obtained during therapy (usually
within 72 hours of its initiation) and at least 7 days after the
completion of treatment are a requisite for the evaluation of
bacteriologic response. The categories of response are eradi-
cation or cure (posttreatment culture demonstrating an
absence of the initial pathogen); persistence or failure (post-
treatment culture yielding the initial pathogen); superinfec-
tion (follow-up culture demonstrating eradication of the ini-
tial pathogen but emergence of a new pathogen); and
relapse. Other possible categories of bacteriologic response
are defined in the General Guidelines [ 1 ], section XIII.C.
3. Final Assessment/Duration of Follow-Up
The test of cure is undertaken at the early follow-up visit,
which should take place —7 days (range, 5-9 days) after the
completion of therapy, unless stated otherwise in the proto-
col. A late follow-up assessment 28-35 days after the com-
pletion of therapy is highly desirable.
I. Methods of Assessing Safety
See General Guidelines [ 1 ], section XIV. In addition to
the elicitation of a complete history and the performance of a
physical examination, a complete blood count, a chemistry
profile, and urinalysis should be undertaken 1 week after
treatment in all cases and at other times during follow-up if
clinically indicated. The suggested laboratory tests represent
the minimal requirements for the evaluation of patients with
bloodstream infections. Additional testing related to preclin-
ical or pharmacological data on the toxicology of the study
drug is warranted to ensure accurate monitoring of safety.
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Requirement at indicated point
Before therapy During therapy After therapy
Clinical Complete history/physical examination Daily assessment Assessment immediately after
therapy, at 5-7 d, and at 1 mo
Laboratory Routine panel* (hematology, chemistry) Selected indices (protocol-specific) Routine panel
Microbiological Baseline cultures: blood (requisite), device, access site Blood culture (at 3-5 d) Blood culture immediately after
therapy, at 7 d, and at 1 mo
Monitoring Serum drug concentrations,
routine parameters (vital signs),
device site (descriptors)
* Panel applicable to specific studies in the protocol.
J. Methods of Presenting and Analyzing Data
See General Guidelines [1], section XVI and Appendix.
Specific subgroup analyses (i.e., removal vs. continued pres-
ence of device during therapy) can be anticipated, and sub-
groups should be defined before initiation of the study.
K. Methods of Assuring Compliance or Ethical Conduct
See General Guidelines [ 1 ], sections IV and XI.E.
VII. INFORMED CONSENT
See General Guidelines [ 1 ], section IV.D. Informed con-
sent must be obtained from participants or their guardians
before enrollment in the study, according to the regulations
of the local institutional review board.
VIII. SUMMARY OF THE GUIDELINE
The main points of this guideline are summarized in ta-
ble 1.
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